ImmuPharma plc (IMM.L) Research

ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, as well as anti-infective applications. Leading its pipeline is Lupuzor, an autophagy immunomodulator, which is presently undergoing Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disease. Beyond its lead candidate, ImmuPharma is advancing BioAMB, a peptide-based drug designed for Amphotericin-B formulations used against fungal infections caused by the aspergillus family. Another product in development is BioCin, a peptide-based antibacterial agent intended for situations of high medical need and as a last-line defense. The company maintains a collaborative relationship with the Centre National de la Recherche Scientifique to develop a peptide technology platform targeting diabetes through glucagon-like peptide -1 agonists and glucagon antagonists for both type I and type II diabetes. ImmuPharma also holds a license and development agreement with Avion Pharmaceuticals LLC. Founded in 1999, ImmuPharma plc is headquartered in London, United Kingdom.

Open ImmuPharma plc (IMM.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.